Last reviewed · How we verify
NCT06788769
Study of Clostridioides Difficile in Infants
trial in Clostridioides Difficile Infection in 300 participants. Currently enrolling.
30 August 2026
Quick facts
| Lead sponsor | Westlake University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 July 2024 |
| Primary completion | 30 August 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across China |
Conditions studied
- Clostridioides Difficile Infection — all drugs for Clostridioides Difficile Infection →
Sponsor
Westlake University
Who can join
Adults 1 Day to 2, any sex, with Clostridioides Difficile Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clostridioides difficile infection (CDI) poses an increasing threat to infant and young child health, with detection rates rising annually. This retrospective study aims to explore the epidemiological characteristics, clinical manifestations, and potential biomarkers of CDI in children aged 0-2 years by examining three cohorts: (1) infants diagnosed with CDI, (2) asymptomatic carriers of C. difficile, and (3) healthy controls. Fecal samples from each group will undergo metagenomic sequencing and metabolomic profiling, coupled with questionnaire-based surveys for risk factor assessment. The findings are anticipated to identify key high-risk factors, elucidate the pathogenic mechanisms underlying infant CDI, and support the development of early diagnostic tools and preventive strategies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06788769
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Clostridioides Difficile Infection
Currently open trials in the same condition.
- NCT07285213 — Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody · Phase 2 · recruiting
- NCT06979609 — Secondary Prevention of Clostridioides Difficile Using Vancomycin · Phase 2, PHASE3 · recruiting
- NCT06859437 — Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain in Nephrology and Transplantati · NA · recruiting
- NCT05330182 — LMN-201 for Prevention of C. Difficile Infection Recurrence · Phase 2, PHASE3 · recruiting
- NCT06306014 — Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in Hi · Phase 1, PHASE2 · recruiting
Other Westlake University trials
Trials by the same sponsor.
- NCT07460687 — Westlake Frequent-sampling Cohort · recruiting
- NCT07373444 — Westlake Aging Cohort (WeAC) · not yet recruiting
- NCT07275671 — Microbiome and Premature Ovarian Insufficiency · recruiting
- NCT05885828 — The PRECISION-T2D Study: Precision Nutrition Study for Type 2 Diabetes · NA · recruiting
- NCT05720650 — B Vitamin Deficiency and Pregnancy Complications · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06788769 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Westlake University
- Last refreshed: 23 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06788769.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing